Egypt has marked a significant milestone in its healthcare system with the nationwide launch of “Trikafta,” a groundbreaking gene therapy for children diagnosed with cystic fibrosis. This new treatment, offered free of charge across all governorates, promises to transform the lives of thousands of young patients suffering from this debilitating genetic condition.
The launch of “Trikafta” follows extensive collaboration between the Ministry of Health and several pharmaceutical partners. The therapy is designed to target the root cause of cystic fibrosis, a genetic disorder that severely affects the lungs and digestive system, leading to chronic respiratory infections, difficulty breathing, and impaired growth. By addressing the underlying genetic mutations, “Trikafta” aims to improve lung function and quality of life for children with the condition.
The drug, which has already shown promising results globally, is now part of Egypt’s public health program, ensuring that families across the nation have access to the latest medical innovations without financial barriers.
The initiative is expected to benefit a significant number of children diagnosed with cystic fibrosis, as the government continues to expand its efforts to address rare and complex diseases. Dr. Abdel Ghaffar further affirmed the commitment to improving access to essential medicines, reinforcing Egypt’s healthcare infrastructure, and supporting the well-being of its citizens.
This move underscores Egypt’s growing focus on genetic medicine and its capacity to integrate international advancements into local healthcare systems. As the Ministry of Health accelerates the implementation of advanced therapies like “Trikafta,” it continues to set an example in the region for innovation in public health management.
